Skip to main content
Premium Trial:

Request an Annual Quote

IDT, Roche 454 Ink Deal for Custom Primers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Integrated DNA Technologies today announced the signing of an exclusive agreement with Roche 454 Life Sciences for the provision of custom primers for 454's GS FLX Titanium Chemistry for use on the GS FLX System and the GS Junior System.

The products are available as FusionPrimers or Rapid Library MID — molecular identification — adaptor oligos, and are used for amplicon or shotgun sequencing, IDT said in a statement. Its unique design software allows researchers to create specific primers to target individual or multiple exons from one or more genes, the company added.

According to IDT, the GS FLX Titanium FusionPrimers have a 25 base pair fixed sequence at the 5' end and enable the sequencing of longer amplicons and increased reads per run. The optional MID sequence acts as a barcode and allows libraries to be multiplexed for subsequent identification.

The GS FLX Titanium RapidLibrary MID Adaptor Oligos are for shotgun sequencing and incorporate MIDs as standard. The adaptors are "especially useful" for sequencing numerous small samples in parallel, lowering the cost of sequencing per sample, IDT said.
Financial terms of the deal were not disclosed.

Two years ago, IDT signed a deal to provide Roche Diagnostics with fusion primers for some 454 sequencing applications.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more